Outcome of children and adolescents with relapsed Hodgkin lymphoma treated with high-dose therapy and autologous stem cell transplantation: the Memorial Sloan Kettering Cancer Center experience

Lisa Giulino-Roth, Tara O’Donohue, Zhengming Chen, Tanya M. Trippett, Elizabeth Klein, Nancy A. Kernan, Rachel Kobos, Susan E. Prockop, Andromachi Scaradavou, Neerav Shukla, Peter G. Steinherz, Alison J. Moskowitz, Craig Moskowitz, Farid Boulad

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

To evaluate outcomes and prognostic markers among children with relapsed Hodgkin lymphoma (HL) treated with autologous stem cell transplant (ASCT), we conducted a retrospective analysis of 36 consecutive pediatric patients treated at Memorial Sloan Kettering Cancer Center from 1989 to 2013. With a median follow-up of 9.6 years, the 10-year overall survival (OS) and event-free survival (EFS) were 74.1 and 67.1% respectively. Absence of B-symptoms, chemotherapy-sensitive disease, and transplant date after 1997 were each associated with superior EFS [HR 0.12 (p =.0015), 0.18 (p =.0039), and 0.17 (p =.0208), respectively]. Childhood Hodgkin International Prognostic Score at relapse (R-CHIPS) was calculated in a subset of patients (n = 22) and a lower score was associated with improved OS (HR 0.29, p =.0352) and a trend toward improved EFS (HR 0.38, p =.0527). In summary, ASCT results in durable remission for the majority of pediatric patients with relapsed HL. R-CHIPS should be evaluated in larger cohorts as a potential predictive tool.

Original languageEnglish (US)
Pages (from-to)1861-1870
Number of pages10
JournalLeukemia and Lymphoma
Volume59
Issue number8
DOIs
StatePublished - Aug 3 2018
Externally publishedYes

Fingerprint

Stem Cell Transplantation
Hodgkin Disease
Disease-Free Survival
Transplants
Stem Cells
Pediatrics
Neoplasms
Survival
Therapeutics
Recurrence
Drug Therapy

Keywords

  • Clinical results
  • lymphoma and Hodgkin disease
  • marrow and stem cell transplantation
  • neoplasia
  • prognostication

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Outcome of children and adolescents with relapsed Hodgkin lymphoma treated with high-dose therapy and autologous stem cell transplantation : the Memorial Sloan Kettering Cancer Center experience. / Giulino-Roth, Lisa; O’Donohue, Tara; Chen, Zhengming; Trippett, Tanya M.; Klein, Elizabeth; Kernan, Nancy A.; Kobos, Rachel; Prockop, Susan E.; Scaradavou, Andromachi; Shukla, Neerav; Steinherz, Peter G.; Moskowitz, Alison J.; Moskowitz, Craig; Boulad, Farid.

In: Leukemia and Lymphoma, Vol. 59, No. 8, 03.08.2018, p. 1861-1870.

Research output: Contribution to journalArticle

Giulino-Roth, L, O’Donohue, T, Chen, Z, Trippett, TM, Klein, E, Kernan, NA, Kobos, R, Prockop, SE, Scaradavou, A, Shukla, N, Steinherz, PG, Moskowitz, AJ, Moskowitz, C & Boulad, F 2018, 'Outcome of children and adolescents with relapsed Hodgkin lymphoma treated with high-dose therapy and autologous stem cell transplantation: the Memorial Sloan Kettering Cancer Center experience', Leukemia and Lymphoma, vol. 59, no. 8, pp. 1861-1870. https://doi.org/10.1080/10428194.2017.1403601
Giulino-Roth, Lisa ; O’Donohue, Tara ; Chen, Zhengming ; Trippett, Tanya M. ; Klein, Elizabeth ; Kernan, Nancy A. ; Kobos, Rachel ; Prockop, Susan E. ; Scaradavou, Andromachi ; Shukla, Neerav ; Steinherz, Peter G. ; Moskowitz, Alison J. ; Moskowitz, Craig ; Boulad, Farid. / Outcome of children and adolescents with relapsed Hodgkin lymphoma treated with high-dose therapy and autologous stem cell transplantation : the Memorial Sloan Kettering Cancer Center experience. In: Leukemia and Lymphoma. 2018 ; Vol. 59, No. 8. pp. 1861-1870.
@article{c8fc1110d537455c9e602a21a37250c4,
title = "Outcome of children and adolescents with relapsed Hodgkin lymphoma treated with high-dose therapy and autologous stem cell transplantation: the Memorial Sloan Kettering Cancer Center experience",
abstract = "To evaluate outcomes and prognostic markers among children with relapsed Hodgkin lymphoma (HL) treated with autologous stem cell transplant (ASCT), we conducted a retrospective analysis of 36 consecutive pediatric patients treated at Memorial Sloan Kettering Cancer Center from 1989 to 2013. With a median follow-up of 9.6 years, the 10-year overall survival (OS) and event-free survival (EFS) were 74.1 and 67.1{\%} respectively. Absence of B-symptoms, chemotherapy-sensitive disease, and transplant date after 1997 were each associated with superior EFS [HR 0.12 (p =.0015), 0.18 (p =.0039), and 0.17 (p =.0208), respectively]. Childhood Hodgkin International Prognostic Score at relapse (R-CHIPS) was calculated in a subset of patients (n = 22) and a lower score was associated with improved OS (HR 0.29, p =.0352) and a trend toward improved EFS (HR 0.38, p =.0527). In summary, ASCT results in durable remission for the majority of pediatric patients with relapsed HL. R-CHIPS should be evaluated in larger cohorts as a potential predictive tool.",
keywords = "Clinical results, lymphoma and Hodgkin disease, marrow and stem cell transplantation, neoplasia, prognostication",
author = "Lisa Giulino-Roth and Tara O’Donohue and Zhengming Chen and Trippett, {Tanya M.} and Elizabeth Klein and Kernan, {Nancy A.} and Rachel Kobos and Prockop, {Susan E.} and Andromachi Scaradavou and Neerav Shukla and Steinherz, {Peter G.} and Moskowitz, {Alison J.} and Craig Moskowitz and Farid Boulad",
year = "2018",
month = "8",
day = "3",
doi = "10.1080/10428194.2017.1403601",
language = "English (US)",
volume = "59",
pages = "1861--1870",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "8",

}

TY - JOUR

T1 - Outcome of children and adolescents with relapsed Hodgkin lymphoma treated with high-dose therapy and autologous stem cell transplantation

T2 - the Memorial Sloan Kettering Cancer Center experience

AU - Giulino-Roth, Lisa

AU - O’Donohue, Tara

AU - Chen, Zhengming

AU - Trippett, Tanya M.

AU - Klein, Elizabeth

AU - Kernan, Nancy A.

AU - Kobos, Rachel

AU - Prockop, Susan E.

AU - Scaradavou, Andromachi

AU - Shukla, Neerav

AU - Steinherz, Peter G.

AU - Moskowitz, Alison J.

AU - Moskowitz, Craig

AU - Boulad, Farid

PY - 2018/8/3

Y1 - 2018/8/3

N2 - To evaluate outcomes and prognostic markers among children with relapsed Hodgkin lymphoma (HL) treated with autologous stem cell transplant (ASCT), we conducted a retrospective analysis of 36 consecutive pediatric patients treated at Memorial Sloan Kettering Cancer Center from 1989 to 2013. With a median follow-up of 9.6 years, the 10-year overall survival (OS) and event-free survival (EFS) were 74.1 and 67.1% respectively. Absence of B-symptoms, chemotherapy-sensitive disease, and transplant date after 1997 were each associated with superior EFS [HR 0.12 (p =.0015), 0.18 (p =.0039), and 0.17 (p =.0208), respectively]. Childhood Hodgkin International Prognostic Score at relapse (R-CHIPS) was calculated in a subset of patients (n = 22) and a lower score was associated with improved OS (HR 0.29, p =.0352) and a trend toward improved EFS (HR 0.38, p =.0527). In summary, ASCT results in durable remission for the majority of pediatric patients with relapsed HL. R-CHIPS should be evaluated in larger cohorts as a potential predictive tool.

AB - To evaluate outcomes and prognostic markers among children with relapsed Hodgkin lymphoma (HL) treated with autologous stem cell transplant (ASCT), we conducted a retrospective analysis of 36 consecutive pediatric patients treated at Memorial Sloan Kettering Cancer Center from 1989 to 2013. With a median follow-up of 9.6 years, the 10-year overall survival (OS) and event-free survival (EFS) were 74.1 and 67.1% respectively. Absence of B-symptoms, chemotherapy-sensitive disease, and transplant date after 1997 were each associated with superior EFS [HR 0.12 (p =.0015), 0.18 (p =.0039), and 0.17 (p =.0208), respectively]. Childhood Hodgkin International Prognostic Score at relapse (R-CHIPS) was calculated in a subset of patients (n = 22) and a lower score was associated with improved OS (HR 0.29, p =.0352) and a trend toward improved EFS (HR 0.38, p =.0527). In summary, ASCT results in durable remission for the majority of pediatric patients with relapsed HL. R-CHIPS should be evaluated in larger cohorts as a potential predictive tool.

KW - Clinical results

KW - lymphoma and Hodgkin disease

KW - marrow and stem cell transplantation

KW - neoplasia

KW - prognostication

UR - http://www.scopus.com/inward/record.url?scp=85035310453&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85035310453&partnerID=8YFLogxK

U2 - 10.1080/10428194.2017.1403601

DO - 10.1080/10428194.2017.1403601

M3 - Article

C2 - 29183202

AN - SCOPUS:85035310453

VL - 59

SP - 1861

EP - 1870

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 8

ER -